msDNA: Revolutionizing the Development of Genetic Medicines
Mediphage’s mission is to alleviate the suffering caused by chronic and genetic diseases by transforming genetic medicine.
The quality of DNA material is paramount in the production of high quality genetic medicines. ministring DNA (msDNAᵀᴹ) represents a novel DNA technology that addresses these quality requirements.
Operating out of the JLABS accelerator in Toronto, Canada, Mediphage is pioneering genetic medicine by leveraging its msDNAᵀᴹ platform. This groundbreaking plasmid technology is driving improvements in the quality of different genetic medicine modalities, subsequently increasing the chances of clinical success.
Lower Immunogenicity
msDNAᵀᴹ has no unnecessary backbone sequences, unlike current conventional DNA vectors, thus benefitting from lower risk of immunogenicity, and lower potential risk of these sequences negatively impacting the quality of final drug products.
Reduced Risk of Insertional Mutagenesis
msDNAᵀᴹ has a linear topology, which has a lower risk of insertional mutagenesis then conventional and novel circular DNA vectors, which have a circular topology.
Higher Fidelity
msDNAᵀᴹ is produced at a higher fidelity compared to other backbone free DNA minivectors which are manufactured using enzymatic reactions. Mediphage manufactures its high-fidelity msDNA platform in Canada using an established E. coli fermentation process.
msDNAᵀᴹ is the ultimate step in the evolution of DNA plasmids
Versatility
msDNAᵀᴹ can be used in a wide array of applications, serving as a versatile tool in various fields. It functions as a drug substance for gene addition, in vivo gene editing, and DNA vaccines. Moreover, msDNAᵀᴹ stands out as the premium starting material for ex vivo cell therapy applications and for the manufacture of mRNA, lentiviral, and rAAV vectors, ensuring high-quality outcomes across diverse biotechnological endeavors.
Therapeutic Programs
Mediphage has an active development pipeline, developing non-viral gene therapies for Hemophilia A, Stargardt Disease, and an undisclosed CNS disorder.
